^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | sasanlimab (PF-06801591) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Published date:
06/27/2023
Excerpt:
Sixty-eight and 38 patients with NSCLC and urothelial carcinoma, respectively, received subcutaneous sasanlimab....The response rate was higher in patients with high PD-L1 expression [ORR (95% CI) 36.4% (10.9% to 69.2%) in PD-L1 ≥50% versus 14.3% (4.0% to 32.7%) in PD-L1 <1%] and high TMB (ORR 41.7% in high TMB versus 8.3% in low TMB) (Table 3; Figure 1)….Subcutaneous sasanlimab at 300 mg q4w was well tolerated with promising clinical efficacy observed.
DOI:
10.1016/j.esmoop.2023.101589
Trial ID:
Source:
Title:
Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Published date:
04/27/2020
Excerpt:
In NSCLC, high baseline CD8 protein expression in certain tumor compartments was associated with better objective response rate (ORR), PFS and OS. High TMB was associated with prior smoking status and better ORR.
DOI:
10.1158/1538-7445.AM2020-CT138
